This promotional website is intended for UK healthcare professionals.
BUCCOLAM® (midazolam) is indicated for the treatment of prolonged, acute, convulsive seizures in adults, adolescents, children and infants aged 3 months and above.1
BUCCOLAM® must only be used by parents/caregivers where the patient has been diagnosed to have epilepsy.1-4
For infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.1-4
